The FDA: Autozone is a prescription drug applicability application

The FDA has approved an application to test the effectiveness of Autozon in treating asthma and chronic obstructive pulmonary disease, according to a release by the agency.

The approval is subject to an additional two-year review.

The FDA said that the application will be considered final for approval and may not be updated without the approval of a third-party third-source source.

The application was filed with the FDA in August 2018.